IFNG and chronic granulomatous disease: IL-17 promotes bacterial clearance in a mouse model of S aureus skin infection [36], IL-1β is associated with successful clearance of bacteremia in humans with SAB [37], and administration of IFN-γ protects against staphylococcal infections in people with chronic granulomatous disease [8].